Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers-Reference-Cited by-同舟云学术

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Published:2015-06-18 Issue:6 Volume:10 Page:e0130142
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Carbognin Luisa,Pilotto Sara,Milella Michele,Vaccaro Vanja,Brunelli Matteo,Caliò Anna,Cuppone Federica,Sperduti Isabella,Giannarelli Diana,Chilosi Marco,Bronte Vincenzo,Scarpa Aldo,Bria Emilio,Tortora Giampaolo

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference57 articles.

1. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;H Dong;Nat Med,2002

2. Enhancement of antitumor immunity by CTLA-4 blockade;DR Leach;Science,1996

3. The blockade of immune checkpoints in cancer immunotherapy;DM Pardoll;Nat Rev Cancer,2012

4. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy;SL Topalian;Cancer cell,2015

5. Improved survival with ipilimumab in patients with metastatic melanoma;FS Hodi;N Engl J Med,2010

Cited by 400 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment;Drug Discovery Today;2024-09

2. Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy;npj Systems Biology and Applications;2024-08-14

3. Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study;Journal of Cardiothoracic Surgery;2024-07-04

4. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1;European Journal of Medicinal Chemistry;2024-05

5. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16